摘要
目的:分析雾化使用重组人干扰素α1b(IFNα1b)治疗儿童呼吸系统疾病的现状,为进一步规范其使用提供参考。方法:从我院医院信息系统(HIS)和电子病历系统提取儿内科2018年9月使用IFNα1b患儿的一般情况、临床诊断、用法用量、疗程、合并疾病等资料,进行回顾性分析。结果:共收集926例使用IFNα1b的儿内科住院患儿,分布在6个病区;平均年龄2.87岁;主要诊断有社区获得性肺炎(44.82%)、支气管肺炎(28.29%)、急性支气管炎(16.85%)等;疗程(5.84±1.58)d;重症病例治疗剂量(1.91±0.60)μg/kg,非重症病例(1.50±0.53)μg/kg。治疗总有效率92.55%,未观察到明显不良反应。结论:儿科使用IFNα1b雾化治疗有较好的临床效果,耐受性和安全性较高,但在剂量、疗程、禁忌证等方面存在一些不合理使用情况,临床应给予重点关注,提高合理用药水平。
Objective: To analyze the current status of inhalation of recombinant human interferon α1 b( IFNα1 b) in the treatment of respiratory diseases in children from pediatrics,so as to provide reference for further regulating the application of IFNα1 b. Methods:From the hospital information system( HIS) and electronic medical record system of our hospital,the general information,clinical diagnosis,usage and dosage,treatment course,and associated diseases of children with IFNα1 b in pediatrics in Sept. 2018 were extracted. And retrospective analysis was conducted. Results: Totally 926 hospitalized children with IFNα1 b were distributed in six wards. The average age was 2. 87 years. The essential diagnosis was community-acquired pneumonia( 44. 82%),bronchopneumonia( 28. 29%) and acute bronchitis( 16. 85%). The treatment duration was( 5. 84±1. 58) d. The dose was( 1. 91±0. 60) μg/kg in severe cases and( 1. 50±0. 53) μg/kg in non-severe cases. The total effective rate was 92. 55%,and no significant adverse drug reactions were observed. Conclusion: Inhalation of IFNα1 b has better clinical effects,higher tolerance and safety,yet there are someirrational application in terms of dose,treatment course and contraindications. Clinical attention should be payed to improve the level of rational medication.
作者
郭文玫
李根
陶婉君
江永贤
李莉
Wang Yang;Ye Qi;Li Sichan;Xu Hua;Sun Dan(Wuhan Children’s Hospital,Tongji Medical College,Huazhong University of Science&Technology,Hubei Wuhan 430016,China)
出处
《儿科药学杂志》
CAS
2019年第12期43-46,共4页
Journal of Pediatric Pharmacy
基金
成都药学会赞邦药学科研基金,编号201703
关键词
儿科
干扰素Α1B
雾化吸入
使用分析
pediatrics
recombinant human interferon α1b
inhalation
application analysis
